Urogen Pharma AI Stock Analysis
Urogen Pharma (UR8) AI Stock Analysis
Urogen Pharma
(Frankfurt:UR8)
No summary available
Urogen Pharma (UR8) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.28B
- Dividend Yield
- ―
- Average Volume (3M)
- 203
- Price to Earnings (P/E)
- -19.8
- Beta (1Y)
- -0.49
- Revenue Growth
- 147.54%
- EPS Growth
- 63.72%
- Country
- Germany
- Employees
- 300
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Urogen Pharma Business Overview & Revenue Model
Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...
Urogen Pharma Earnings Call Summary
The call was strongly constructive, led by 35% sequential Zosturi revenue growth, expanding prescriber and repeat-use metrics, major UGN-103 regulatory progress, pipeline advancement, improved financial results, and management's expectation of profitability and positive cash flow in the fourth quarter. The principal challenges were Jelmyto revenue pressure from a one-time adjustment and clinical-trial competition, elevated operating expenses, adoption barriers, and near-term seasonality. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, UroGen updated Jelmyto net product revenue guidance to approximately $90 million, is not issuing full-year Zosturi guidance, and is maintaining full year operating expense guidance of $260 million to $270 million including $20 million to $24 million of noncash share based compensation, with operating expenses expected to land toward the upper end of the guidance range; the company expects quarter over quarter revenue growth for Zosturi in the fourth quarter of 26, is comfortable with where consensus sits for the full year for Zosturi, and anticipates achieving profitability and generating positive cash flow in the fourth quarter of 26. For 2027, the company is not issuing guides for Zosturi, although it said growing $15 to $20 million this year is a reasonable framework, and described Jelmyto as likely to be within that 100 to 150 range long term.
Urogen Pharma Risk Analysis
Urogen Pharma disclosed 81 risk factors in its most recent earnings report. Urogen Pharma reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksUrogen Pharma Peers Comparison
Overall Rating
PBYI64Neutral
VSTM54Neutral
NUVB49Neutral
ZLAB49Neutral
KURA48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | $401.70M | 16.32 | 17.52% | ― | 9.35% | -37.15% | |
| 54Neutral | $1.03B | -4.42 | -359.49% | ― | 649.65% | 54.01% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.41B | -10.11 | -49.11% | ― | 654.19% | 39.07% | |
| 49Neutral | $3.24B | -14.26 | -31.11% | ― | 0.25% | 8.33% | |
| 48Neutral | $713.90M | -2.35 | -336.24% | ― | -23.76% | -33.09% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:UR8 | Urogen Pharma | 23.15 | 3.15 | 15.75% | |
| VSTM | Verastem Inc | 8.18 | -0.97 | -10.60% | |
| PBYI | Puma Biotechnology | 7.77 | 2.81 | 56.65% | |
| KURA | Kura Oncology | 7.77 | -3.08 | -28.39% | |
| ZLAB | Zai Lab Ltd | 24.60 | 3.68 | 17.59% | |
| NUVB | Nuvation Bio Inc | 3.99 | -0.68 | -14.56% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
